NCT06103734View on ClinicalTrials.gov

A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,280

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 2, 2027

Study Completion Date

August 2, 2027

Conditions
Migraine
Interventions
COMBINATION_PRODUCT

Zavegepant 10 mg

4 doses of zavegpant 10 mg intranasal spray device

COMBINATION_PRODUCT

Placebo - Control 1

3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device

COMBINATION_PRODUCT

Placebo - Control 2

3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY